Swiss-Italian biopharmaceutical firm Newron Pharmaceuticals secures up to €15M via share subscription agreement with an institutional investor.

Swiss-Italian biopharmaceutical firm Newron Pharmaceuticals enters into a share subscription agreement with an institutional investor, raising up to EUR 15 million in proceeds via up to 2.05 million newly issued shares. The fund initially subscribes to 750,000 shares at EUR 7.33 per share, with an option to subscribe up to an additional 1.3 million shares by January 31, 2025. Newron plans to utilize the funds raised to support its activities beyond current key value inflection points.

March 14, 2024
8 Articles

Further Reading